This suggests that CDK5 inhibitors could be a promising approach in the treatment of neurodegenerative disorders such as Alzheimer's disease, where tau phosphorylation and neuroinflammation play critical roles in the pathology. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.